Ensign Peak Advisors
CGON icon

Ensign Peak Advisors’s CG Oncology CGON Stock Holding History

Ensign Peak Advisors’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27M Sell
380,546
-75,466
-17% -$4.93M 0.04% 270
2026
Q1 		$30.9M Sell
456,012
-74,746
-14% -$4.23M 0.06% 245
2025
Q4 		$22M Buy
530,758
+134,279
+34% +$5.56M 0.04% 279
2025
Q3 		$16M Hold
396,479
– – 0.03% 353
2025
Q2 		$10.3M Buy
396,479
+262,079
+195% +$6.32M 0.02% 462
2025
Q1 		$3.29M Buy
134,400
+73,835
+122% +$2.08M 0.01% 747
2024
Q4 		$1.74M Hold
60,565
– – ﹤0.01% 1008
2024
Q3 		$2.29M Hold
60,565
– – ﹤0.01% 888
2024
Q2 		$1.91M Buy
+60,565
New +$2.1M ﹤0.01% 927

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ensign Peak Advisors's CGON Position: Q2 2026 in Review

Ensign Peak Advisors reduced its CG Oncology (CGON) stake by 17% in Q2 2026, selling an estimated $4.93M and leaving 380,546 shares worth $27M. The position accounts for 0.04% of the portfolio, ranked #270.

Ensign Peak Advisors first reported a position in CGON in Q2 2024 and has held it in 9 quarters since. The position peaked at $30.9M in Q1 2026. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Ensign Peak Advisors held 380,546 shares of CG Oncology worth $27M as of Q2 2026.
  • Ensign Peak Advisors sold 75,466 CG Oncology shares in Q2 2026, an estimated $4.93M.
  • CG Oncology made up 0.04% of Ensign Peak Advisors's portfolio in Q2 2026, its #270 holding.
  • Ensign Peak Advisors first reported a position in CG Oncology in Q2 2024 and has held it in 9 quarters since.
  • Ensign Peak Advisors's CG Oncology position peaked at $30.9M in Q1 2026.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.